William Jacot
About
William Jacot is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, William Jacot has authored 224 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 170 papers in Oncology, 116 papers in Pulmonary and Respiratory Medicine and 81 papers in Cancer Research. Recurrent topics in William Jacot's work include Advanced Breast Cancer Therapies (69 papers), Breast Cancer Treatment Studies (54 papers) and HER2/EGFR in Cancer Research (52 papers). William Jacot is often cited by papers focused on Advanced Breast Cancer Therapies (69 papers), Breast Cancer Treatment Studies (54 papers) and HER2/EGFR in Cancer Research (52 papers). William Jacot collaborates with scholars based in France, United States and Italy. William Jacot's co-authors include Pierre‐Jean Lamy, Séverine Guiu, Gilles Romieu, Catherine Alix‐Panabières, Simon Thézenas, Florence Boissière‐Michot, Caroline Mollévi, Laure Cayrefourcq, Klaus Pantel and Evelyne Lopez‐Crapez and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.
In The Last Decade
William Jacot
202 papers receiving 4.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| William Jacot France | 34 | 2.7k | 1.4k | 1.2k | 1.1k | 433 | 224 | 4.2k | ||
| Yeon Hee Park South Korea | 34 | 2.5k 0.9× | 1.3k 1.0× | 1.5k 1.3× | 1.1k 1.1× | 410 0.9× | 196 | 4.1k | ||
| Florence Dalenc France | 33 | 2.6k 1.0× | 1.6k 1.1× | 1.3k 1.1× | 1.3k 1.2× | 243 0.6× | 209 | 4.5k | ||
| Erica L. Mayer United States | 31 | 2.6k 1.0× | 997 0.7× | 1.2k 1.0× | 1.4k 1.3× | 305 0.7× | 144 | 4.7k | ||
| Paul Frankel United States | 34 | 1.9k 0.7× | 967 0.7× | 658 0.5× | 1.8k 1.6× | 388 0.9× | 214 | 4.1k | ||
| Mario Giuliano Italy | 34 | 2.4k 0.9× | 1.2k 0.9× | 1.4k 1.1× | 1.0k 0.9× | 197 0.5× | 109 | 3.8k | ||
| Andrea Rocca Italy | 33 | 2.3k 0.8× | 911 0.7× | 1.3k 1.0× | 1.1k 1.1× | 212 0.5× | 135 | 4.1k | ||
| Nina J. Karlin United States | 15 | 2.2k 0.8× | 969 0.7× | 1.1k 0.9× | 1.4k 1.3× | 252 0.6× | 47 | 4.1k | ||
| Anne O’Neill United States | 30 | 1.8k 0.7× | 822 0.6× | 979 0.8× | 505 0.5× | 620 1.4× | 89 | 3.5k | ||
| Benjamin Esterni France | 32 | 2.2k 0.8× | 683 0.5× | 1.0k 0.8× | 1.4k 1.3× | 380 0.9× | 75 | 4.4k | ||
| Luis E. Raez United States | 37 | 2.2k 0.8× | 1.7k 1.3× | 1.2k 0.9× | 1.8k 1.7× | 490 1.1× | 224 | 4.6k |
Countries citing papers authored by William Jacot
Since
Specialization
Citations
This map shows the geographic impact of William Jacot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Jacot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Jacot more than expected).
Fields of papers citing papers by William Jacot
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by William Jacot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Jacot. The network helps show where William Jacot may publish in the future.
Co-authorship network of co-authors of William Jacot
This figure shows the co-authorship network connecting the top 25 collaborators of William Jacot. A scholar is included among the top collaborators of William Jacot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Jacot. William Jacot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bottosso, Michele, Gaia Griguolo, Séverine Guiu, et al.. (2025). Temporal evolution of breast cancer brain metastases treatments and outcomes. npj Breast Cancer. 11(1). 20–20.
2.
Velázquez, Carolina, Béatrice Orsetti, Geneviève Rodier, et al.. (2025). Replication-Poison Treatment in BRCA1 -Deficient Breast Cancer Causes MRE11 Over-Resection That Induces Single-Stranded DNA Accumulation and Mitotic Catastrophe. Cancer Research. 85(8). 1410–1423.
3.
Ueno, Naoto T., Filipa Cardoso, Toshinari Yamashita, et al.. (2024). 188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC). ESMO Open. 9. 103210–103210.
4.
Meglio, Antonio Di, Julie Havas, Martina Pagliuca, et al.. (2024). Patterns of depressive symptoms among survivors of early-stage breast cancer (BC).. Journal of Clinical Oncology. 42(16_suppl). 12009–12009.
5.
Curigliano, Giuseppe, Xichun Hu, Rebecca Dent, et al.. (2024). Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).. Journal of Clinical Oncology. 42(17_suppl). LBA1000–LBA1000.
6.
Bidard, François‐Clément, Frédérique Berger, Mónica Arnedos, et al.. (2024). Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.. Journal of Clinical Oncology. 42(16_suppl). TPS1139–TPS1139.
7.
Meunier, Lucy, Eléonora De Martin, Bénédicte Delire, et al.. (2024). CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment. JHEP Reports. 6(7). 101098–101098.
8.
Campos‐Mora, Mauricio, William Jacot, Geneviève Garcin, et al.. (2023). NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells. Frontiers in Immunology. 14. 1199594–1199594.
9.
Chen, Jessica W., William Jacot, Javier Cortés, et al.. (2023). ER +, HER2 − advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology. 17(10). 2000–2016.
10.
Modi, Shanu, William Jacot, Hiroji Iwata, et al.. (2023). 376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. Annals of Oncology. 34. S334–S335.
11.
Bottosso, Michele, Gaia Griguolo, Federica Miglietta, et al.. (2023). Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases. British Journal of Cancer. 128(7). 1286–1293.
12.
Bobrie, Angélique, José Ramos, Caroline Mollévi, et al.. (2022). Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. Cancers. 14(19). 4829–4829.
13.
Manoir, Stanislas du, Béatrice Orsetti, William Jacot, et al.. (2022). In high‐grade ovarian carcinoma, platinum‐sensitive tumor recurrence and acquired‐resistance derive from quiescent residual cancer cells that overexpress CRYAB , CEACAM6, and SOX2 . The Journal of Pathology. 257(3). 367–378.
14.
Alcaraz, Lindsay B., Aude Mallavialle, Caroline Mollévi, et al.. (2022). SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity. International Journal of Cancer. 152(6). 1243–1258.
15.
Boissière‐Michot, Florence, et al.. (2021). CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. Cancers. 13(10). 2328–2328.
16.
Darlix, Amélie, Christophe Hirtz, Caroline Mollévi, et al.. (2021). Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. International Journal of Cancer. 149(8). 1605–1618.
17.
Jacot, William, Evelyne Lopez‐Crapez, Caroline Mollévi, et al.. (2020). BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers. 12(4). 828–828.
18.
Jacot, William, Florence Dalenc, Evelyne Lopez‐Crapez, et al.. (2019). PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast Cancer Research and Treatment. 177(3). 659–667.
19.
Maran-Gonzalez, Aurélie, Marie Viala, Nelly Firmin, et al.. (2019). <p>Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?</p>. Cancer Management and Research. Volume 11. 10353–10373.
20.
Baselga, José, Susan Dent, Javier Cortés, et al.. (2018). Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology. 36(18_suppl). LBA1006–LBA1006.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yeon Hee Park Breakdown of academic impact, for papers by Florence Dalenc Breakdown of academic impact, for papers by Erica L. Mayer Breakdown of academic impact, for papers by Paul Frankel Breakdown of academic impact, for papers by Mario Giuliano Breakdown of academic impact, for papers by Andrea Rocca Breakdown of academic impact, for papers by Nina J. Karlin Breakdown of academic impact, for papers by Anne O’Neill Breakdown of academic impact, for papers by Benjamin Esterni Breakdown of academic impact, for papers by Luis E. Raez